Medtronic reported nearly $9.8 billion in fiscal 2027 first-quarter revenue, up 13.7% year over year, and raised its full-year organic revenue growth outlook. The quarter included an extra week; shares have fallen 3% since the report, and the dividend yield is 3.2%.
Medtronic said the extra week versus the prior-year quarter added approximately $570 million to organic growth. Earnings per share rose 40.7% to $1.14. The company raised its full-year organic revenue forecast to 7.25%–7.75%, from 6.75%–7.25%, and lifted the low end of its non-GAAP diluted EPS outlook to $5.94 from $5.90. Cardiovascular revenue grew 18.9% organically to $3.93 billion, including an 88% increase in cardiac ablation; neuroscience grew 9.3% and medical-surgical 10.2%.
Motley Fool argues the 3.2% yield—slightly more than triple the S&P 500 average—and a lower valuation than peers could appeal to long-term investors; Medtronic’s payout ratio is about 59%, and it has raised its dividend for 49 consecutive years, including a 1.4% increase this year. Shares are down more than 7% in 2026 and over 32% in five years. The article flags MiniMed spin-off costs, spending on Hugo robotic surgery, and competition and pricing pressure in neuroscience. Medtronic also bought Scientia Vascular for $550 million and SPR Therapeutics for $650 million, and exercised an option to acquire CathWorks.
